STOCK TITAN
  1. Home
  2. Sec-filings
  3. PFE
  4. [Form 4] PFIZER INC Insider Trading Activity

Pfizer (NYSE: PFE) CEO receives 24 phantom stock units in deferred plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 24 Phantom Stock Units SSP on common stock equivalents. Each unit represents one phantom share of Pfizer common stock, with the grant recorded at $25.33 per unit.

These units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. They are settled in cash after Bourla’s separation from service and can be moved into an alternative investment account at any time. Following this grant, his reported phantom stock unit balance is 773,297 units.

Positive

  • None.

Negative

  • None.
Insider BOURLA ALBERT
Role Chairman & CEO
Type Security Shares Price Value
Grant/Award Phantom Stock Units SSP 24 $25.33 $607.92
Holdings After Transaction: Phantom Stock Units SSP — 773,297 shares (Direct, null)
Footnotes (1)
  1. Each unit represents one phantom share of common stock. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Phantom units granted 24 units Grant of Phantom Stock Units SSP on 2026-05-15
Grant price per unit $25.33 per unit Recorded transaction price for phantom units
Phantom units after transaction 773,297 units Total Phantom Stock Units SSP held following grant
Phantom Stock Units SSP financial
"Phantom Stock Units SSP"
Nonfunded Deferred Compensation and Supplemental Savings Plan financial
"acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan"
settled in cash financial
"are settled in cash following the reporting person's separation from service"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BOURLA ALBERT
(Last)(First)(Middle)
66 HUDSON BOULEVARD EAST
ATTN: CORPORATE SECRETARY
(Street)
NEW YORK NEW YORK 10001-2192
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Phantom Stock Units SSP(1)05/15/2026A24 (2) (2)Common Stock24$25.33773,297D
Explanation of Responses:
1. Each unit represents one phantom share of common stock.
2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
/s/ Shanice A. Reid, by power of atty., for Albert Bourla05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pfizer (PFE) CEO Albert Bourla report in this Form 4 filing?

Albert Bourla reported receiving a grant of 24 Phantom Stock Units SSP tied to Pfizer common stock. The grant was priced at $25.33 per unit and increased his reported phantom stock units balance to 773,297 units under a deferred compensation plan.

What are Phantom Stock Units SSP reported by Pfizer (PFE) CEO Bourla?

Phantom Stock Units SSP are bookkeeping units that mirror Pfizer common stock rather than actual shares. Each unit represents one phantom share and, in this case, will be settled in cash after the executive’s separation from service according to Pfizer’s deferred compensation plan.

How many phantom stock units does Pfizer (PFE) CEO hold after this transaction?

After this grant, Albert Bourla is reported as holding 773,297 Phantom Stock Units SSP. This total reflects the addition of 24 newly granted units, each linked to one phantom share of Pfizer common stock under the company’s deferred compensation structure.

How will Albert Bourla’s Pfizer (PFE) phantom stock units be settled?

The phantom stock units will be settled in cash following Albert Bourla’s separation from service. Under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, these units track common stock value but do not deliver actual shares, only cash payments later.

Can Pfizer (PFE) CEO Bourla move these phantom stock units into other investments?

Yes. The filing states these phantom stock units may be transferred into an alternative investment account at any time. This flexibility is provided under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan that governs this award for the executive.

Was this Pfizer (PFE) Form 4 transaction an open-market stock purchase?

No. The transaction is classified as a grant or award acquisition of Phantom Stock Units SSP, not an open-market purchase. The units are part of a nonfunded deferred compensation plan and will be settled in cash instead of acquiring Pfizer shares in the market.